|
WO2021067714A2
|
|
Methods for determining antibody affinity and binding kinetics using vlps or live viruses attached to biosensors
|
|
WO2020226831A1
|
|
Inactivated virus compositions and zika vaccine formulations
|
|
US2021023204A1
|
|
Methods for preventing dengue and hepatitis a
|
|
WO2021034349A1
|
|
Methods for preventing dengue and hepatitis a
|
|
WO2020132510A1
|
|
Norovirus vaccine formulations and methods
|
|
WO2020106358A1
|
|
Novel anti-zika virus antibodies and uses thereof
|
|
WO2020051328A1
|
|
Assay for determining antibody response to dengue virus
|
|
CA3111332A1
|
|
Dengue vaccine unit dose and administration thereof
|
|
WO2020041192A1
|
|
Vlp formulations
|
|
US2020069751A1
|
|
Dengue vaccine unit dose and administration thereof
|
|
AU2018375173A1
|
|
Zika vaccines and immunogenic compositions, and methods of using the same
|
|
US2020360505A1
|
|
Zika Vaccines and Immunogenic Compositions, and Methods of Using the Same
|
|
WO2018045344A1
|
|
Methods for producing virus for vaccine production
|
|
TW201807191A
|
|
Compositions and methods for stabilizing flaviviruses with improved formulations
|
|
CA3020484A1
|
|
Compositions and methods of vaccination against dengue virus in children and young adults
|
|
BR112018069079A2
|
|
live attenuated alphavirus constructs and methods and uses thereof
|
|
AU2017241590A1
|
|
Compositions and methods for stabilizing alphaviruses with improved formulations
|
|
AU2016250345A1
|
|
Method of conferring a protective immune response to norovirus
|
|
AU2016213859A1
|
|
Methods and compositions for live attenuated viruses
|
|
EP3256571A1
|
|
Methods for producing virus for vaccine production
|
